Dimitriou, F., Orloff, M. M., Koch Hein, E. C., Cheng, P. F., Hughes, I. F., Simeone, E., Montazeri, K., Grover, P., Mehmi, I., Gerard, C. L., Gaudy-Marqueste, C., Grob, J.-J., Michielin, O., Hamid, O., Long, G. V., Sullivan, R., Kapiteijn, E., Johnson, D. B., Ascierto, P. A., … Dummer, R. (2025). Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. European Journal of Cancer, 214, 115161. https://doi.org/10.1016/j.ejca.2024.115161

Ventin, M., Cattaneo, G., Arya, S., Jia, J., Gelmi, M. C., Sun, Y., Maggs, L., Ksander, B. R., Verdijk, R. M., Boland, G. M., Jenkins, R. W., Haq, R., Jager, M. J., Wang, X., Ryeom, S., & Ferrone, C. R. (2024). Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting. Clinical Cancer Research, 30(15), 3243–3258. https://doi.org/10.1158/1078-0432.ccr-24-0071

Fahmy, L. M., Schreidah, C. M., McDonnell, D. E., Carvajal, R. D., Magro, C. M., & Geskin, L. J. (2024). Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma. Dermatology Online Journal, 29(6). https://doi.org/10.5070/d329662993

Carvajal, R. D., Sacco, J. J., Jager, M. J., Eschelman, D. J., Olofsson Bagge, R., Harbour, J. W., Chieng, N. D., Patel, S. P., Joshua, A. M., & Piperno-Neumann, S. (2023). Advances in the clinical management of uveal melanoma. Nature Reviews Clinical Oncology, 20(2), 99–115. https://doi.org/10.1038/s41571-022-00714-1

Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J. M., Rioth, M., Johnson, D. B., Luke, J. J., Espinosa, E., Leyvraz, S., Collins, L., Goodall, H. M., Ranade, K., Holland, C., Abdullah, S. E., … Sato, T. (2022). Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nature Medicine, 28(11), 2364–2373. https://doi.org/10.1038/s41591-022-02015-7

Chen, L. N., & Carvajal, R. D. (2022). Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma. Expert Review of Anticancer Therapy, 22(10), 1017–1027. https://doi.org/10.1080/14737140.2022.2124971

Carvajal, R. D., Nathan, P., Sacco, J. J., Orloff, M., Hernandez-Aya, L. F., Yang, J., Luke, J. J., Butler, M. O., Stanhope, S., Collins, L., McAlpine, C., Holland, C., Abdullah, S. E., & Sato, T. (2022). Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of Clinical Oncology, 40(17), 1939–1948. https://doi.org/10.1200/jco.21.01805

Liu, A. W., Wei, A. Z., Maniar, A. B., & Carvajal, R. D. (2022). Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. Expert Opinion on Biological Therapy, 22(8), 997–1004. https://doi.org/10.1080/14712598.2022.2031970